Dr Brett P. Monia, a founder of Ionis Pharmaceuticals Inc., and head of drug discovery and the company’s inotersen program, is to become the company’s chief operating officer, effective Jan. 15, 2018. He will replace B. Lynne Parshall, who will become senior strategic advisor to Ionis and remain a member of the board of directors of Ionis and Akcea Therapeutics Inc.
ThromboGenics NV has appointed Dr Susan Schneider as chief medical officer, and Vinciane Vangeersdaele as chief commercial officer. Schneider brings nearly 15 years of experience in clinical drug development to ThromboGenics. Most recently, she was vice president and therapeutic area head of retina and glaucoma at Allergan PLC. Vangeersdaele has over 15 years’ experience in a variety of pharmaceutical sales and marketing leadership roles, the latest being the head of the ophthalmology franchise Europe at Novartis AG
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?